Smart Biomaterials for Targeted Cancer Therapy

This is the authors' abstract. We don't add key points for this paper.

Cancer is one of the most formidable challenges in medicine, often constrained by the limitations of conventional treatments like chemotherapy and radiotherapy, which may induce severe side effects and lead to drug resistance. The emergence of smart biomaterials offers a revolutionary approach to targeted cancer therapy through precise drug delivery, minimizing systemic toxicity, and enhancing therapeutic outcomes. These biomaterials are engineered to respond to specific internal stimuli such as pH, temperature, or enzymes, and external triggers like light or magnetism provide unparalleled versatility in addressing the complex tumor microenvironment. Recent innovations encompass stimuli-responsive hydrogels, nanoparticle-based systems, and oxygen-releasing scaffolds, which overcome barriers such as tumor hypoxia and multidrug resistance. Nanogels, metal-organic frameworks, and biomolecule-functionalized materials exemplify the potential for multifunctional platforms that combine diagnosis and therapy. Moreover, innovations such as DNA-based nanorobots and AI (artificial intelligence)-driven biomaterial design facilitate highly personalized and adaptive treatments. Despite significant advancements in the past decades, challenges persist in translating these materials from laboratory research to clinical application due to biocompatibility, scalability, and regulatory constraints. This review explores the state-of-the-art advancements in smart biomaterials for cancer treatment, their mechanisms of action, and the potential to transform oncology.